EANM guidelines on the use of [18F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders.

Cristina Nanni; Christophe M Deroose; Sona Balogova; Constantin Lapa; Nadia Withofs; Manil Subesinghe; Bastien Jamet; Elena Zamagni; Davide Ippolito; Michel Delforge; Francoise Kraeber-Bodéré

doi:10.1007/s00259-024-06858-9

EANM guidelines on the use of [¹⁸F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders.

Cristina Nanni, Christophe M Deroose, Sona Balogova, Constantin Lapa, Nadia Withofs, Manil Subesinghe, Bastien Jamet, Elena Zamagni, Davide Ippolito, Michel Delforge, Francoise Kraeber-Bodéré

PET Imaging Centre Facility

Research output: Contribution to journal › Article › peer-review

Abstract

We provide updated guidance and standards for the indication, acquisition, and interpretation of [¹⁸F]FDG PET/CT for plasma cell disorders. Procedures and characteristics are reported and different scenarios for the clinical use of [¹⁸F]FDG PET/CT are discussed. This document provides clinicians and technicians with the best available evidence to support the implementation of [¹⁸F]FDG PET/CT imaging in routine practice and future research.

Original language	English
Journal	European Journal of Nuclear Medicine and Molecular Imaging
DOIs	https://doi.org/10.1007/s00259-024-06858-9
Publication status	E-pub ahead of print - 29 Aug 2024

Access to Document

10.1007/s00259-024-06858-9

Cite this

Nanni, C., Deroose, C. M., Balogova, S., Lapa, C., Withofs, N., Subesinghe, M., Jamet, B., Zamagni, E., Ippolito, D., Delforge, M., & Kraeber-Bodéré, F. (2024). EANM guidelines on the use of [¹⁸F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders. European Journal of Nuclear Medicine and Molecular Imaging. Advance online publication. https://doi.org/10.1007/s00259-024-06858-9

@article{a135a86a10364abf929a37cb0bfe40ab,

title = "EANM guidelines on the use of [18F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders.",

abstract = "We provide updated guidance and standards for the indication, acquisition, and interpretation of [18F]FDG PET/CT for plasma cell disorders. Procedures and characteristics are reported and different scenarios for the clinical use of [18F]FDG PET/CT are discussed. This document provides clinicians and technicians with the best available evidence to support the implementation of [18F]FDG PET/CT imaging in routine practice and future research. ",

author = "Cristina Nanni and Deroose, {Christophe M} and Sona Balogova and Constantin Lapa and Nadia Withofs and Manil Subesinghe and Bastien Jamet and Elena Zamagni and Davide Ippolito and Michel Delforge and Francoise Kraeber-Bod{\'e}r{\'e}",

note = "Publisher Copyright: {\textcopyright} The Author(s) 2024.",

year = "2024",

month = aug,

day = "29",

doi = "10.1007/s00259-024-06858-9",

language = "English",

journal = "European Journal of Nuclear Medicine and Molecular Imaging",

issn = "1619-7070",

publisher = "SPRINGER",

}

Nanni, C, Deroose, CM, Balogova, S, Lapa, C, Withofs, N, Subesinghe, M, Jamet, B, Zamagni, E, Ippolito, D, Delforge, M & Kraeber-Bodéré, F 2024, 'EANM guidelines on the use of [¹⁸F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders.', European Journal of Nuclear Medicine and Molecular Imaging. https://doi.org/10.1007/s00259-024-06858-9

TY - JOUR

T1 - EANM guidelines on the use of [18F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders.

AU - Nanni, Cristina

AU - Deroose, Christophe M

AU - Balogova, Sona

AU - Lapa, Constantin

AU - Withofs, Nadia

AU - Subesinghe, Manil

AU - Jamet, Bastien

AU - Zamagni, Elena

AU - Ippolito, Davide

AU - Delforge, Michel

AU - Kraeber-Bodéré, Francoise

PY - 2024/8/29

Y1 - 2024/8/29

N2 - We provide updated guidance and standards for the indication, acquisition, and interpretation of [18F]FDG PET/CT for plasma cell disorders. Procedures and characteristics are reported and different scenarios for the clinical use of [18F]FDG PET/CT are discussed. This document provides clinicians and technicians with the best available evidence to support the implementation of [18F]FDG PET/CT imaging in routine practice and future research.

AB - We provide updated guidance and standards for the indication, acquisition, and interpretation of [18F]FDG PET/CT for plasma cell disorders. Procedures and characteristics are reported and different scenarios for the clinical use of [18F]FDG PET/CT are discussed. This document provides clinicians and technicians with the best available evidence to support the implementation of [18F]FDG PET/CT imaging in routine practice and future research.

UR - http://www.scopus.com/inward/record.url?scp=85204174696&partnerID=8YFLogxK

U2 - 10.1007/s00259-024-06858-9

DO - 10.1007/s00259-024-06858-9

M3 - Article

C2 - 39207486

SN - 1619-7070

JO - European Journal of Nuclear Medicine and Molecular Imaging

JF - European Journal of Nuclear Medicine and Molecular Imaging

ER -

EANM guidelines on the use of [¹⁸F]FDG PET/CT in diagnosis, staging, prognostication, therapy assessment, and restaging of plasma cell disorders.

Abstract

Access to Document

Other files and links

Fingerprint

Cite this